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To investigate the effects of gabapentin, a structural analog of γ-amino butyric acid
(GABA), on the inflammatory response of lipopolysaccharide (LPS)-stimulated rabbit
corneal cells (SIRC) and on endotoxin-induced uveitis (EIU) in rabbits. We investigated
the LPS-induced expression of several inflammatory mediators, such as TNF-α, IL-1β,
cPLA2, COX-2, and PGE2 in the SIRC cells with or without gabapentin treatment.
Gabapentin treatment significantly (p < 0.05) attenuated cytokines production, cPLA2
activation, COX-2 expression, and PGE2 levels in SIRC. EIU was induced by an
intraocular injection of 0.1 µg of LPS in albino rabbit eye. After 7 and 24 h from
LPS injection clinical signs of ocular inflammation were examined by slit lamp with or
without topical treatment of 0.5% gabapentin. Tears, aqueous, cornea, conjunctiva,
and iris-ciliary body were collected and inflammatory biomarkers assessed. Topical
treatment with gabapentin significantly (p < 0.05) reduced clinical signs and biomarkers
of inflammation compared with the LPS group both at 7 and 24 h. In conclusion, the
results generated in the present study suggest that ophthalmic formulation based on
gabapentin may be useful in the treatment of inflammatory conditions associated to
ocular pain such as uveitis, and that clinical studies to evaluate this possibility may be
warranted.
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INTRODUCTION
Gabapentin, a structural analog of γ-amino butyric acid (GABA), targeting α2δ1 subunit of voltage-
sensitive calcium channels, has therapeutic effect for neurological and psychiatric disorders such as
epilepsy, anxiety, and neuropathic pain. This latter is also present in the eye and has been reported
in patients affected by dry eye disease or diabetes or Sjögren syndrome (Rosenthal et al., 2009).
Further, neuropathic ocular pain can be elicited by UV exposure or chemical insults. The effect
of gabapentin on pain as recently linked to the anti-inflammatory action of the drug. It has been
demonstrated (Lee et al., 2013) that gabapentin is able to reduce pro-inflammatory mediators (e.g.,
TNF-α, IL-1β, and IL-6) and up-regulates anti-inflammatory cytokine IL-10 in a rat model of
neuropathic pain. More recently (Dias et al., 2014) it has been showed that gabapentin reverses
inflammatory process in well-known acute mouse models of inflammation.
Frontiers in Pharmacology | www.frontiersin.org 1 April 2017 | Volume 8 | Article 173
fphar-08-00173 April 1, 2017 Time: 16:55 # 2
Anfuso et al. Gabapentin Attenuates Ocular Inflammation
Inflammation is a non-specific response to injury that includes
a variety of functional and molecular mediators, including
recruitment and/or activation of inflammatory cells and release
of inflammatory mediators such as cytokines (e.g., TNF-α),
interleukins (e.g., IL-1β, IL-6), enzymes [e.g., cyclooxygenases
(COXs)], and prostaglandins (PGs) (e.g., PGE2). These latter
are synthesized by COXs, bifunctional enzymes which contain
both cyclooxygenase and peroxidase activity and exist as
distinct isoforms referred to as COX-1 and COX-2 (Smith
et al., 2000) starting from arachidonic acid (AA), in turn
hydrolyzed by phospholipases A2 (PLA2s). Moreover, AA plays
a key role in inflammation and neurodegenerative disorders
(Sun et al., 2004). Among the three major classes of PLA2s
(secretory, calcium-independent and calcium-dependent) in
the mammalians, the group IV calcium-dependent cytosolic
PLA2α (cPLA2α) has received the most attention because of its
expression in all mammalian cells and its active participation in
cell metabolism (Sun et al., 2014). Following the Ca++binding
to its C-2 domain, cPLA2 undergoes a number of post-
translational modifications, such as phosphorylation on Ser-505,
-727, and -515 and S-nitrosylation after the NO-interaction
(Linkous and Yazlovitskaya, 2010). The aim of the study was
to investigate the effects of gabapentin on ocular inflammatory
models using lipopolysaccharide (LPS)-induced damage both
in vitro and in vivo. In particular, we used rabbit corneal cells
[Seruminstitute Rabbit Cornea (SIRC)] and a rabbit model of
uveitis. Endotoxin-induced uveitis (EIU) represents a valuable
experimental model of acute ocular inflammation characterized
by release of several inflammatory biomarkers. We investigated
the effect of gabapentin both in corneal cells challenging with LPS
and in EIU assessing the levels of TNF-α, IL-6, IL-1β, and PGE2.
MATERIALS AND METHODS
Materials
Gabapentin was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). LPS (L2880) from Escherichia coli
O127:B8 were obtained from Sigma–Aldrich Chemical Co.
(St Louis, MO, USA). Anti-rabbit IL-1β and anti-mouse TNF-α
antibodies were purchased from Abcam Inc. (Cambridge, MA,
USA). Anti-rabbit p-cPLA2, cPLA2, COX-2 antibodies were
purchased from Cell Signaling Technology (CST).
Cell Cultures
Statens Seruminstitut rabbit corneal (SIRC) epithelial cells
(ATCC CCL-60) were cultured in minimum essential medium
with Earle’s salts, L-glutamine, and non-essential amino acids
supplemented [Eagle’s Minimum Essential Medium (ATCC R© 30-
2003TM] with 10% activated fetal bovine serum (FBS, 10108-
165, GIBCO), incubated at 37◦C in a humidified atmosphere
of 5% CO2. SIRC cells were seeded into 6-wells plates for 24 h
before the experiment at a density of 1.2 × 105 cells/well in
2.0 ml of medium. Culture medium was exchanged every other
day, and cultures were maintained until sub-confluence. For all
experiments, cells were pre-incubated in serum-free medium
(SFM) for 1 h with 10 µg/ml gabapentin (this concentration was
chosen based on cell viability assay) and then, the inflammatory
stimulus was induced with LPS (1 µg/ml) for different times. In
addition, in order to examine the gabapentin effect on baseline
cytokines level, SIRC cells were incubated with the drug alone
without LPS.
Analysis of Cell Viability
The MTT assay was employed to assess rabbit corneal cell
viability after treatment with gabapentin or LPS. Cells were
seeded in 96-well plates at a density 2 × 104 cells per well and
incubated overnight at 37◦C before experiment. Subsequently,
different concentrations of gabapentin (5, 10, 100, 1000 µg/ml)
were added to each well except the well with control solution,
for 24 and 48 h. In a second set of experiments was also assayed
the toxicity of LPS (1–10–100 µg/ml) after 24 h. After incubation
with the substances, 10 µl MTT [3-(4,5-dimethylthiazol-2-yl)2,5-
diphenyltetrazolium bromide] reagent (5 mg/ml) was added to
each well and the plates were incubated for 3 h at 37◦C. The
formazan crystals were extracted with 100 µl DMSO and plates
were shaken for 10 min. The absorbance was measured at 570 nm
with plate reader (Biotek Instruments, Elx-800). Cell viability was
calculated as a percentage of the control.
Western Blot Analysis
Protein was extracted from SIRC cells as follows: cells were
washed with PBS (pH 7.4), centrifuged at 1000 × g for 3 min,
suspended in protein extraction buffer and incubated on ice for
30 min. After sonication, extract was centrifuged at 8,000 × g
for 15 min. Protein samples (30 µg/lane) were subjected to
SDS-PAGE and, after transfer to nitrocellulose membranes, were
incubated as described previously (Lupo et al., 2007; Scuderi
et al., 2008) with antibody against TNF-α, IL-1β, p-cPLA2,
cPLA2, COX-2, β-actin overnight at 4◦C followed by incubation
with horseradish peroxidase conjugated secondary antibody, goat
anti-rabbit IgG for IL-1β, p-cPLA2, cPLA2, COX-2 and goat anti-
mouse IgG for TNF-α and β-actin. After washing, with TBS-T,
protein expression was visualized with the Super Signal West
Pico Chemiluminescence detection system (Thermo Scientific,
Rockford, IL, USA). β-actin served as the loading control. Bands
were analyzed using Image J software (Version1.43, Broken
Symmetry Software, Bethesda, MD, USA).
PGE2 Measurement
PGE2 was measured in culture medium using a competitive
binding ELISA, according to the manufacturer’s instructions
(Abcam Inc., Cambridge, MA, USA). In particular, the SFM was
harvested after incubation of SIRC with gabapentin and LPS
(as described in experimental design) for 24 h. The amount of
PGE2 was extrapolated from a standard curve (according the
manufacturer’s instructions). All experiments were performed in
triplicate.
Endotoxin-Induced Uveitis (EIU) Model
Male New Zealand albino rabbits weighing 2–2.5 kg (Harlan,
Italy) were used. Animals were housed in single cage upon
arrival in the facilities (in a light and temperature controlled
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room) with tap water and standard chow provided ad libitum.
Animal procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Catania,
and conformed to the Association for Research in Vision and
Ophthalmology (ARVO) resolution on the use of animals in
research. Uveitis was induced by an intravitreal injection of LPS
(0.1 µg/10 µl of E. coli 0111:B4; Sigma–Aldrich, Milan, Italy).
Before LPS injection, rabbits were anesthetized by intravenous
injection of 5 mg/kg Zoletil R© (2.5 mg/kg tiletamine HCl and
2.5 mg/kg zolazepam HCl; Virbac, Milan, Italy) and one drop
of local anaesthetic (Novesina R©, Novartis, Origgio, Italy) was
administered to the eye. An ophthalmic formulation of 0.5%
gabapentin was prepared in an isotonic buffered solution (pH
7.0; 298 mOsm) and a multiple treatment (50 µl/instillation)
was carried out (one instillation 30 min before LPS and four
treatments after LPS). The dose used in the present study
was chosen based on preliminary dose-ranging study (data not
shown). Seven or 24 h after LPS injection tears were obtained with
glass capillary tubes (Behring Diagnostics, Marburg, Germany).
After that, the animals were killed (Tanax R©; Intervet, Milan, Italy)
and aqueous, conjunctiva, cornea, and iris-ciliary body collected.
Care was taken to obtained tear samples avoiding stimulated tear
production. Ten microliters of tears were collected from each eye
and stored at -80◦C until analysis.
Clinical Score and Aqueous Protein
Levels
The clinical signs of ocular inflammation were examined by slit
lamp (Sbisà, Firenze, Italy) and were graded on a scale of 0–4,
according to the scoring system described by Ruiz-Moreno et al.
(1992). Briefly the score was: 0 = no inflammatory reaction;
1 = discrete inflammatory reaction; 2 = moderate dilation of
the iris and conjunctival vessels; 3 = intense iridal hyperemia,
with flare in the anterior chamber; 4 = the same clinical signs as
grade 3 plus the presence of fibrinoid exudation in the pupillary
area, with intense flare in the anterior chamber. Clinical signs
assessment was performed 15 m before the 7th and 24th h from
intravitreal injection of LPS. Aqueous samples were collected
from both eyes with a 30-gauge needle and protein levels assessed
by a bicinchoninic acid (BCA) protein assay kit (Beyotime
Institute of Biotechnology, Jiangsu, China).
Biomarkers Assessment
Ocular tissues (cornea, conjunctiva. and iris-ciliary body) were
cut and lysed in 500 µL of tissue extraction reagent containing
protease inhibitors (Invitrogen) with ULTRA-TURRAX. The
samples were sonicated on ice and centrifuged twice (15,000 × g
at 4◦C, 20 min). The supernatant was assayed for levels of
pro-inflammatory cytokines with commercial ELISA kits for
TNF-α, IL-6, IL-1β (Quantikine kit; life technologies); before
ELISA assay, total protein content in the ocular tissues was
measured using the BCA protein assay kit. The ratio of cytokine
to total protein (pg/mg) was calculated. All estimations were
performed in duplicate. The TNF-α level was evaluated in tears
with commercial ELISA kits (Quantikine kit; life technologies)
at 7 and 24 h after injection of LPS; for the analysis were used
5 µL of the sample and values were expressed as pg/mL. In the
aqueous humor, the TNF-α level was evaluated at 7 h and 24 h
after injection of LPS with commercial ELISA kits (Quantikine
kit; MybioSource) using 50 µL of the sample and values were
expressed as pg/mL. PGE2 levels in aqueous humor samples were
measured using an ELISA kit (Quantikine kit, Abcam) at 7 and
24 h after injection of LPS. The values were expressed as pg/mL
according to the instruction manual.
Statistical Analysis
Data are presented as mean ± SD. A statistical analysis was
performed with GraphPad Prism (GraphPad Software, Inc., San
Diego, CA, USA). One-way ANOVA, followed by Tukey’s test
was applied for parametric data; Kruskal–Wallis test, followed
by Mann–Whitney test was performed for non-parametric data.
A P-value less than 0.05 was considered statistically significant.
RESULTS
Cell Viability
MTT assays were carried out in order to assess the effect of
gabapentin on SIRC viability (Figure 1). 5, 10, and 100 µg/ml
gabapentin did not affect cell viability, either at 24 h or at
48 h. Gabapentin at 1 mg/ml concentration caused a decrease
in viability by 30 and 46% at 24 and 48 h, respectively. The
data were confirmed by Trypan blue staining (data not shown).
Based on these results, 10 µg/ml has been chosen for all in vitro
experiments.
Effects of Gabapentin on LPS-induced
TNF-α and IL-1β Protein Expression
Seruminstitute Rabbit Cornea were treated with 1 µg/ml
LPS to induce an inflammatory response (Figure 2, see the
dose-response MTT viability curve into the box in the left of
the figure). LPS increased TNF-α and IL-1β expression by 2.1-
FIGURE 1 | Effects of gabapentin on corneal cells viability. SIRC were
seeded in 96-well plates at a density of 2 × 104 cells per well and incubated
overnight at 37◦C before experiment. Subsequently, different doses of
gabapentin were added to each well for 24 and 48 h, as described in section
“Materials and Methods.” Values represent mean ± SD, §p < 0.01 vs. CTRL.
One-way ANOVA, followed by Tukey’s test.
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FIGURE 2 | Effects of gabapentin on cytokines production by lipopolysaccharide (LPS) in corneal cells. SIRC were pre-incubated in serum-free medium
(SFM) for 1 h with gabapentin (10 µg/ml), and the inflammatory stimulus was induced with LPS (1 µg/ml) for 24 h. Lysates were prepared for Western blot analysis
as described in section “Materials and Methods.” BOX: Effect of LPS on SIRC viability after 24 h incubation; for the subsequent experiments was chosen the
1 µg/ml not toxic dose. (A) Representative immunoblot images of TNF-α, IL-1β, and β-actin following LPS treatment with or without gabapentin. (B,C) Densitometric
analysis of TNF-α and IL-1β protein levels after adjusting for β-actin band intensity. Values represent mean ± SD, ∗p < 0.05 vs. LPS, §p < 0.01 vs. CTRL. One-way
ANOVA, followed by Tukey’s test.
and 1.4-fold, respectively (Figure 2). This effect was significantly
attenuated by gabapentin treatment (by 52 and 36% for TNF-α
and IL-1β, respectively). These data demonstrate a positive effect
of gabapentin to counteract inflammatory cytokines elicited by
LPS. Gabapentin (10 µg/ml) alone did not elicited expression of
TNF-α and IL-1β.
PLA2 Protein Expression/Activation
Western blot analyses of cPLA2 and phospho-cPLA2 in SIRC
lysates from LPS with or without gabapentin in time-course
experiments (5, 15, and 30 min, and 24 h) are reported
in Figure 3. Immunoblots revealed the cPLA2 total protein
expression was almost comparable in all samples within the same
slot of incubation, regardless of LPS or gabapentin presence
(panel A). LPS caused significant increases in the expression
of the phosphorylated protein (except at 5 min), that is to say
the activated form of cPLA2 (1.44, 2.1, and 1.8 p-cPLA2/cPLA2
ratio at 15 and 30 min and 24 h, respectively) and the increase
in enzyme activity (Figure 3). Interestingly, by 15 min onward
in subsequent incubation time points, gabapentin caused a
significant (p < 0.05) reduction of the phosphorylation levels
of the protein. These data support the idea that gabapentin is
able to modulate the activation of an upstream enzyme in the
intracellular cascade of events that lead, through the release of
AA to the synthesis of key inflammatory mediators such as
eicosanoids.
COX-2 and PGE2 in Corneal Cells
Cyclooxygenases-2 expression in SIRC (Figures 4A,B) after
30 min, 6 and 18 h from LPS was evaluated (no changes in COX-1
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FIGURE 3 | Effects of gabapentin on cPLA2 activation by LPS in
corneal cells. SIRC were pre-incubated in SFM for 1 h with gabapentin
(10 µg/ml) and the inflammatory stimulus was induced with LPS (1 µg/ml) for
the different time points reported in figure. Lysated were prepared for Western
blot analysis, as described in section “Materials and Methods.”
(A) Representative immunoblot images of phospho-cPLA2 (p-cPLA2) and
total-cPLA2 after LPS treatment with or without gabapentin.
(B) Phospho-cPLA2/cPLA2 band intensity ratios of protein levels. Values
represent mean ± SD, ∗p < 0.05 vs. LPS, §p < 0.01 vs. CTRL. One-way
ANOVA, followed by Tukey’s test.
protein expression were observed; data not shown). Conversely,
LPS-stimulated SIRC significantly expressed inducible COX-
2 total protein by 2.8-, 3.0-, and 3.9-fold at 30 min, 6 and
18 h, respectively, compared to control (no LPS) (Figure 4B).
Gabapentin treatment (10 µg/ml) significantly (p < 0.05)
reduced the LPS-conditioned SIRC COX-2 overexpression by
43% (30 min), 40% (6 h), and 62% (18 h). These data confirmed
the positive effect of gabapentin to contrast the production
of inflammatory enzymes such as COX-2. At this regard, we
evaluated PGE2 production, measured in supernatants of all
culture models incubated for 24 h (Figure 4C). Gabapentin alone
in SIRC (without LPS) had no effect on PGE2 production. As
expected, LPS-induced a significant increase in PGE2 production
by 3.0-fold compared to control. Gabapentin treatment in LPS-
stimulated SIRC caused a significant (p < 0.05) reduction in
PGE2 levels.
Clinical Score and Aqueous Protein
Levels
Ocular inflammation elicited by LPS caused a significant
(p < 0.05) damage of eye’s tissues after 7 h still evident at 24 h
(Figure 5A). Topical treatment with gabapentin significantly
reduced clinical signs of inflammation compared with the LPS
group both at 7 and 24 h (Figure 5A). Furthermore, LPS injection
induced a significant (p < 0.01) increase of protein levels in
FIGURE 4 | Effects of gabapentin on COX-2 and PGE2 in corneal cells.
SIRC were pre-incubated in SFM for 1 h with gabapentin (10 µg/ml) and the
inflammatory stimulus was induced with LPS (1 µg/ml) for the time points
reported in figure. Lysated were prepared for Western blot analysis, as
described in section “Materials and Methods.” In a separate set of
experiments, the supernatants were collected to assess PGE2 after 24 h, as
described in section “Materials and Methods.” Representative immunoblot
images of COX-2 after LPS exposure with or without gabapentin (A).
Densitometric analysis of COX-2 protein level after adjusting for β-actin band
intensity (B). ELISA analysis of PGE2 levels after 24 h of LPS exposure with or
without gabapentin (C). Values represent mean ± SD, ∗p < 0.05 vs. LPS,
§p < 0.01 vs. CTRL. One-way ANOVA, followed by Tukey’s test.
the aqueous humor particularly after 7 h (Figure 5B) which is
significantly (p< 0.05) reverted by gabapentin treatment.
Inflammatory Biomarkers
At 7 and 24 h after LPS injection we observed a significant
(p < 0.01 vs. control) increase of TNF-α levels in tears,
cornea, aqueous, and iris-ciliary body that was reversed by
topical treatment of gabapentin (Figure 6). Furthermore, the
effects of topical gabapentin on IL-6 and IL-1β in ocular
tissues were assessed in rabbit with EIU (Figure 7). Previous
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FIGURE 5 | Effects of topical gabapentin on clinical score and aqueous
protein levels in experimental uveitis. Clinical scores were evaluated at 7
and 24 h after LPS injection (A), see section “Materials and Methods” for
more details. Aqueous protein levels from all groups measured at 7 and 24 h
after LPS injection (B). Values represent mean ± SD, ∗p < 0.05 vs. LPS,
§p < 0.01 vs. CTRL. Kruskal–Wallis test followed by Mann–Whitney test (A);
one-way ANOVA followed by Tukey’s test (B).
studies (Mo et al., 1998; Brito et al., 2006) reported that
the peak of aqueous IL-1β levels in rabbit with EIU was
around 18 h after endotoxin injection, and IL-6 did not change
at 24 h. In accordance with these reports we observed a
significant (p < 0.01) peak of IL-6 and IL-1β in the aqueous
in rabbit with EIU at 7 and 24 h, respectively. Topical
treatment with gabapentin significantly (p < 0.05) attenuated
the release of IL-6 and IL-1β in the aqueous of rabbit with EIU
(Figure 7). Finally, gabapentin was able to significantly reduce
the PGE2 levels in the aqueous elicited by endotoxin injection
(Figure 8).
DISCUSSION
In the present study we demonstrated that gabapentin inhibited
ocular inflammation both in vitro and in vivo paradigms. In
particular, gabapentin was able to counteract the inflammatory
process elicited by LPS in rabbit corneal cells and rabbit’s eye.
Inflammation usually has beneficial effects on an acute
basis, but can have unwanted effects if abiding chronically.
Uveitis is the fourth cause of blindness in developed countries,
and it represents a typical chronic ocular inflammation with
a difficult management in terms of pharmacological therapy.
Gabapentin is structurally related to the neurotransmitter
gamma aminobutyric acid (GABA) but does not bind to the
GABA receptors. Gabapentin is a drug with approved indications
for epilepsy, seizures and neuropathic pain. Its mechanism of
action is through binding to calcium channels and modulating
the influx of calcium and thereby bestowing antiepileptic
and analgesic effects. It is not clear if the anti-inflammatory
effect of gabapentin is related to calcium modulation rather
than other mechanisms such as stimulation of endogenous
anti-oxidants like GSH, inhibition of NF-kB, block of NMDA
receptor or activation of adenosine A1 receptor (Abdel-Salam
and Sleem, 2009; Kim et al., 2009; Yang et al., 2012; Dias
et al., 2014; Wang et al., 2014; Martins et al., 2015; Xu et al.,
2017). Phosphorylation and calcium concentrations are the
effectors modulating the activity of cPLA2 and recent studies
have highlighted the role of PLAs2 as potential therapeutic
target in inflammation and in other serious disorders, and the
increase of PLA2 has been linked with the severity of the disease
(Yarla et al., 2015). AA is released from phospholipids by the
action of different isoforms of phospholipase A2s (PLA2s) and
converted to PGs or leukotrienes (LTs) by the action of COXs and
5-lipoxygenase, respectively. These downstream products play
key roles in governing cell migration and proliferation, as well
as inflammation (Dennis et al., 2011; Anfuso et al., 2014; Lupo
et al., 2014). Actually, four main groups of phospholipases
are known, which include the secretory, the calcium-
independent, the cytosolic and the lipoprotein-associated
phospholipases A2.
Release of AA has been shown to accumulate in response
to ischemia in the eye (Birkle and Bazan, 1989; Remé et al.,
1994). There is only a little knowledge about PLA2 expression
in other parts of the eye, in addition to the retina (Castagnet
and Giusto, 1993; Van Themsche et al., 2001; Kolko et al., 2007).
cPLA has been identified in the human cornea (Landreville et al.,
2004), while, in the conjunctiva, cPLA2 is mainly localized in the
surface of the epithelium, probably participating in the protection
against risks caused by mechanical wear and tear stress (Helin
et al., 2008). In an in vitro retinoblastoma human triple culture
model of angiogenesis, tumor cells induced in human retinal
endothelium the increase in cPLA2proteinexpression (Lupo et al.,
2014). As showed in the in vitro studies, LPS caused an increase
expression of the cPLA2 active form and gabapentin significantly
lowered the phosphorylation levels of the protein, supporting
the idea that gabapentin was able to modulate the intracellular
cascade of events that lead to the release of AA for the synthesis of
key inflammatory eicosanoids mediators. Two main isoforms of
cyclooxygenase exist, COX-1 and COX-2 (Simmons et al., 2004),
being COX-3 still largely unknown (Davies et al., 2004). COX-1
is constitutively expressed in many tissues and plays a key role
in the management of homeostasis. On the contrary, COX-2 is
an inducible isoform and is activated in response to extracellular
stimuli such as growth factors and pro-inflammatory cytokines
(Simmons et al., 2004). It has been shown that cPLA2 and
COX-2 co-localized in the perinuclear area (Pardue et al.,
2003). Moreover, IL-1β and TNFα activate COX-2 and stimulate
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FIGURE 6 | Effects of topical gabapentin on TNF-α levels in experimental uveitis. TNF-α levels in tears (A,B), cornea (C,D), aqueous humor (AH) (E,F), and
iris-ciliary body (ICB) (G,H) at 7 and 24 h after LPS injection. Values represent mean ± SD, ∗p < 0.05 vs. LPS, §p < 0.01 vs. CTRL. One-way ANOVA, followed by
Tukey’s test.
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FIGURE 7 | Effects of topical gabapentin on IL-6 and IL-1β levels in experimental uveitis. IL-6 (A) and IL-1β (B) levels in cornea, conjunctiva, and ICB (G, H)
at 7 and 24 h, respectively, after LPS injection. Values represent mean ± SD, ∗p < 0.05 vs. LPS, §p < 0.01 vs. CTRL. One-way ANOVA, followed by Tukey’s test.
FIGURE 8 | Effect of topical gabapentin on aqueous PGE2 levels in experimental uveitis. PGE2 levels in aqueous humor at 7 h (A) and 24 h (B) after LPS
injection. Values represent mean ± SD, ∗p < 0.05 vs. LPS, §p < 0.01 vs. CTRL. One-way ANOVA, followed by Tukey’s test.
signaling pathways leading to cPLA2 phosphorylation and AA. At
this regard, TNFα-stimulated phosphorylation of cPLA2involves
the c-Jun and p38 MAP kinase pathways (Hernández et al.,
1999). In an endotoxin-induced uveitis rodent model and in
human ARPE-19 cells LPS-activated, an increasing of COX-2,
IL-6, and IL-8 gene expression were found (Girol et al., 2013).
Moreover, mice underwent to adverse environmental conditions
showed high COX-2 and PGE synthase mRNA levels on the
ocular surface (Shim et al., 2012). In accordance with this data,
LPS-stimulated SIRC significantly expressed inducible COX-2
total protein and gabapentin treatment dramatically reduced the
COX-2 synthesis induction. Moreover, gabapentin treatment in
LPS-stimulated SIRC caused a significant reduction in PGE2
levels.
Several findings have been highlighted the role of gabapentin
in reducing inflammation in several experimental paradigms
(Dias et al., 2014). Recently, Dias et al. (2014) demonstrated that
gabapentin decreases the paw edema induced by carrageenan,
dextran, and 48/80 in mice. Furthermore, these authors showed
that gabapentin inhibited levels of pro-inflammatory cytokines
(TNF-α and IL-1β) and neutrophil infiltration. We showed, for
the first time, that gabapentin attenuates ocular inflammation
elicited by LPS both rabbit corneal cells culture and in rabbit
eye. The effects of gabapentin may be due, at least in part,
to the inhibition of inflammatory cytokines such as TNF-α,
IL-6, and IL-1β. We also demonstrated that tear TNF-α was
inhibited by gabapentin in EIU model. The data on TNF-α,
IL-6, and IL-1β are in accordance with the findings generated
by Lee et al. (2013) in different inflammatory paradigms. The
anti-inflammatory effects of gabapentin may be dependent on a
combination of pharmacologic properties of this molecule that
could be due to the block of some specific cytokines, particularly
TNF-α. Similarly to what we observed in SIRC we showed a
significant (p < 0.05) inhibition of PGE2 levels in aqueous
humor of rabbit with EIU. It is noteworthy that TNF-α is key
actor in ocular inflammation, TNF-α triggers activation of cPLA2
and then enhancing the synthesis of PGE2 (Van Putten et al.,
2001). We demonstrated that ocular inflammation elicited by
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LPS was significantly attenuated by gabapentin treatment both
in SIRC and rabbit eye. TNF-α, a well-known hallmark of ocular
inflammation, was significantly reduced by gabapentin treatment
in vitro and in vivo after endotoxin challenging. In particular,
gabapentin reduced TNF-α levels in tears, aqueous, cornea, and
iris-ciliary body of rabbit with EIU.
CONCLUSION
The results generated in the present study suggest that
ophthalmic formulation based on gabapentin may be useful in the
treatment of inflammatory conditions associated to ocular pain
such as uveitis, and that clinical studies to evaluate this possibility
may be warranted.
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